What do you see as current and future challenges? And this relies on improving the patient management systems we have in place and collaboration across healthcare.
#Nightingale syndrome how to#
Our focus is not only how to find more effective treatments, but also how we can be more effective in delivering the treatments we have to our patients. We have assessed and followed a cohort of individuals with HFpEF recruited from primary care practices, and have over 140 interviews with patients, their carers, and clinicians across the different sectors of the healthcare system, exploring their experiences and problems and soliciting their opinions on possible solutions. We believed that there was a great deal that could be done to improve the management of patients with HFpEF, but we first needed to understand what was happening in practice and the challenges to providing effective care. My lecture presents the work we have been doing – a programme of qualitative and quantitative research in HFpEF – and the importance of taking a multidisciplinary approach. Tell us something about your lecture topic Our understanding of heart failure (especially with reduced ejection fraction) has also evolved – I can remember when beta blockers were contraindicated in their treatment – but there is still much to be done, especially in HFpEF. I was fortunate to work in a centre involved in the Thrombolysis in Myocardial Infarction (TIMI) trials and to see the results unfold. The introduction of thrombolysis in the 1980s changed the picture for these patients. When I started clinical practice, there were no real treatments for people who had had a myocardial infarction. What has kept me fascinated are the extraordinary changes in treatment I have witnessed throughout my time in the specialty.
What first drew me to cardiology in the 1970s were the patients, the experiences they were having, and how much there was to learn. Presenter of the 2021 ESC Florence Nightingale Lecture in Nurse-Led Research, Christi Deaton, Professor of Nursing at the University of Cambridge and Cambridge University Hospitals, UK, is passionate about developing effective systems and clinical practice to optimise the management of patients with heart failure with preserved ejection fraction (HFpEF).
0 kommentar(er)
